|
1
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kwok JM, Peck B, Monteiro LJ, Schwenen HD,
Millour J, Coombes RC, Myatt SS and Lam EW: FOXM1 confers acquired
cisplatin resistance in breast cancer cells. Mol Cancer Res.
8:24–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang J, Wang Z, Hu X, Wang B, Wang L,
Yang W, Liu Y, Liu G, Di G, Hu Z, et al: Cisplatin and gemcitabine
as the first line therapy in metastatic triple negative breast
cancer. Int J Cancer. 136:204–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yazlovitskaya EM and Persons DL:
Inhibition of cisplatin-induced ATR activity and enhanced
sensitivity to cisplatin. Anticancer Res. 23:2275–2279.
2003.PubMed/NCBI
|
|
6
|
Wei Q, Dong G, Yang T, Megyesi J, Price PM
and Dong Z: Activation and involvement of p53 in cisplatin-induced
nephrotoxicity. Am J Physiol Renal Physiol. 293:F1282–F1291. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshida K, Ozaki T, Furuya K, Nakanishi M,
Kikuchi H, Yamamoto H, Ono S, Koda T, Omura K and Nakagawara A:
ATM-dependent nuclear accumulation of IKK-alpha plays an important
role in the regulation of p73-mediated apoptosis in response to
cisplatin. Oncogene. 27:1183–1188. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pegram MD, Lipton A, Hayes DF, Weber BL,
Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA
and Slamon DJ: Phase II study of receptor-enhanced chemosensitivity
using recombinant humanized anti-p185HER2/neu monoclonal antibody
plus cisplatin in patients with HER2/neu-overexpressing metastatic
breast cancer refractory to chemotherapy treatment. J Clin Oncol.
16:2659–2671. 1998.PubMed/NCBI
|
|
9
|
Sui M, Zhang H and Fan W: The role of
estrogen and estrogen receptors in chemoresistance. Curr Med Chem.
18:4674–4683. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mattingly KA, Ivanova MM, Riggs KA,
Wickramasinghe NS, Barch MJ and Klinge CM: Estradiol stimulates
transcription of nuclear respiratory factor-1 and increases
mitochondrial biogenesis. Mol Endocrinol. 22:609–622. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cam H, Balciunaite E, Blais A, Spektor A,
Scarpulla RC, Young R, Kluger Y and Dynlacht BD: A common set of
gene regulatory networks links metabolism and growth inhibition.
Mol Cell. 16:399–411. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kang D, Kim SH and Hamasaki N:
Mitochondrial transcription factor A (TFAM): Roles in maintenance
of mtDNA and cellular functions. Mitochondrion. 7:39–44. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hallberg BM and Larsson NG: TFAM forces
mtDNA to make a U-turn. Nat Struct Mol Biol. 18:1179–1181. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang Z, Schumaker LM, Egorin MJ, Zuhowski
EG, Guo Z and Cullen KJ: Cisplatin preferentially binds
mitochondrial DNA and voltage-dependent anion channel protein in
the mitochondrial membrane of head and neck squamous cell
carcinoma: Possible role in apoptosis. Clin Cancer Res.
12:5817–5825. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Byrski T, Huzarski T, Dent R, Gronwald J,
Zuziak D, Cybulski C, Kladny J, Gorski B, Lubinski J and Narod SA:
Response to neoadjuvant therapy with cisplatin in BRCA1-positive
breast cancer patients. Breast Cancer Res Treat. 115:359–363. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hsieh CY, Santell RC, Haslam SZ and
Helferich WG: Estrogenic effects of genistein on the growth of
estrogen receptor-positive human breast cancer (MCF-7) cells in
vitro and in vivo. Cancer Res. 58:3833–3838. 1998.PubMed/NCBI
|
|
18
|
Ström A, Hartman J, Foster JS, Kietz S,
Wimalasena J and Gustafsson JA: Estrogen receptor beta inhibits
17beta-estradiolstimulated proliferation of the breast cancer cell
line T47D. Proc Natl Acad Sci USA. 101:1566–1571. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferguson AT, Lapidus RG, Baylin SB and
Davidson NE: Demethylation of the estrogen receptor gene in
estrogen receptor-negative breast cancer cells can reactivate
estrogen receptor gene expression. Cancer Res. 55:2279–2283.
1995.PubMed/NCBI
|
|
20
|
Doane AS, Danso M, Lal P, Donaton M, Zhang
L, Hudis C and Gerald WL: An estrogen receptor-negative breast
cancer subset characterized by a hormonally regulated
transcriptional program and response to androgen. Oncogene.
25:3994–4008. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li L and Yu AQ: The functional role of
peroxiredoxin 3 in reactive oxygen species, apoptosis, and
chemoresistance of cancer cells. J Cancer Res Clin Oncol.
141:2071–2077. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hosoya N and Miyagawa K: Targeting DNA
damage response in cancer therapy. Cancer Sci. 105:370–388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Silver DP, Richardson AL, Eklund AC, Wang
ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, et
al: Efficacy of neoadjuvant Cisplatin in triple-negative breast
cancer. J Clin Oncol. 28:1145–1153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Funato T, Kozawa K, Kaku M and Sasaki T:
Modification of the sensitivity to cisplatin with c-myc
over-expression or down-regulation in colon cancer cells.
Anticancer Drugs. 12:829–834. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fraser M, Bai T and Tsang BK: Akt promotes
cisplatin resistance in human ovarian cancer cells through
inhibition of p53 phosphorylation and nuclear function. Int J
Cancer. 122:534–546. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bradford CR, Zhu S, Ogawa H, Ogawa T,
Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG and Carey TE: P53
mutation correlates with cisplatin sensitivity in head and neck
squamous cell carcinoma lines. Head Neck. 25:654–661. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Niedner H, Christen R, Lin X, Kondo A and
Howell SB: Identification of genes that mediate sensitivity to
cisplatin. Mol Pharmacol. 60:1153–1160. 2001.PubMed/NCBI
|
|
29
|
Funato T, Kozawa K, Kaku M and Sasaki T:
Modification of the sensitivity to cisplatin with c-myc
over-expression or down-regulation in colon cancer cells.
Anticancer Drugs. 12:829–834. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fraser M, Bai T and Tsang BK: Akt promotes
cisplatin resistance in human ovarian cancer cells through
inhibition of p53 phosphorylation and nuclear function. Int J
Cancer. 122:534–546. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Olivero OA, Semino C, Kassim A,
Lopez-Larraza DM and Poirier MC: Preferential binding of cisplatin
to mitochondrial DNA of Chinese hamster ovary cells. Mutat Res.
346:221–230. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kroemer G, Dallaporta B and Resche-Rigon
M: The mitochondrial death/life regulator in apoptosis and
necrosis. Annu Rev Physiol. 60:619–642. 1998. View Article : Google Scholar : PubMed/NCBI
|
